Overview

A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study

Status:
Completed

Trial end date:
2016-03-25

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the long-term safety and efficacy of ASP015K in subjects with Rheumatoid Arthritis (RA) who have completed a preceding Phase 2 ASP015K RA study.

Phase:

Phase 2

Details

Lead Sponsor:

Astellas Pharma Global Development, Inc.

Collaborator:

Janssen Biotech, Inc.

Treatments:

Peficitinib